Remove tag kol
article thumbnail

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Pharmaceutical Technology

DMTs for MS have a high price tag, particularly in the US. Key opinion leaders (KOLs) interviewed by GlobalData emphasised that the high cost of DMTs for MS can have a major impact on patients, their families, and society. However, they cannot provide a cure and have a very limited impact on halting disease progression.

Marketing 246
article thumbnail

Versanis’ bimagrumab, first-in-class obesity therapy, enters Phase IIb of development

Pharmaceutical Technology

Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies. Furthermore, many patients with obesity have other comorbidities, so this reduction in the frequency of treatment days is all the more essential to this subset of patients in ameliorating compliance to treatment.

article thumbnail

Insights From Medical Affairs Interactions

pharmaphorum

Is it possible to collate & synthesise such insights from all these Medical Affairs activities, in a way that enables you to see the truth that may be spread across many different KOL/HCP interactions? The short answer is “Sure!”. But a few things to consider when designing the process.

52